Eszopiclone

CHEMBL1522 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

388.8 g/mol

LogP

0.5

Phase

4

This non-benzodiazepine sleep medication works by enhancing GABA activity in the brain to help people fall asleep and stay asleep through the night. It is approved for the longer-term treatment of insomnia.

Peso Molecular

388,8000 g/mol

LogP

0,50

TPSA

91,80 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Parkinson's Disease Migraine Schizophrenia Generalized Anxiety Disorder Insomnia Multiple Sclerosis Type 2 Diabetes Hypertension Major Depressive Disorder

Mecanismo de Ação

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1

InChI

InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1

Molecular Formula

C17H17ClN6O3

HBD / HBA

- / 7

Ligações Rotacionáveis

3

Átomos Pesados

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

This non-benzodiazepine sleep medication works by enhancing GABA activity in the brain to help people fall asleep and stay asleep through the night. It is approved for the longer-term treatment of insomnia.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Eszopiclone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1522. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 969472. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Eszopiclone no PillFYI

Estrutura

Dados Rápidos

Fórmula: C17H17ClN6O3
Sinônimos: 1

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.